25 March 2019
Our European team of life sciences specialists discuss the guidance available from the European Commission, and national governments and regulatory agencies for pharmaceutical and medical devices regulation in the event of a no-deal Brexit.
In this webinar, speakers from Taylor Wessing and Willkie Farr & Gallagher focus on key factors decision-makers need to be aware of when considering settlement.
Judith Krens and Misja Boeken discuss a recent a request for a preliminary injunction based on the Dutch supplementary protection certificate for darunavir made to the District Court of the Hague.
Paul England outlines the conflict between the EU Commission and the Enlarged Board of the EPO about whether the products of essentially biological processes are patentable.
© Taylor Wessing